Praxis Precision Medicines
Clinical trials sponsored by Praxis Precision Medicines, explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with rare epilepsy: drug trial targets seizure control Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New hope for babies with rare seizure disorder: drug trial targets SCN2A gene Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New epilepsy drug vormatrigine enters final testing phase Results expected Jan 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
Can a new daily pill tame focal seizures?
Disease control CompletedThis trial is testing whether an experimental medication called PRAX-628 can reduce the frequency of focal seizures in adults with epilepsy who are already taking one to three other seizure medications. Participants will receive either PRAX-628 or a placebo for 12 weeks, with the…
Phase 2/3 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Will a tablet deliver the same dose as a capsule? a bioavailability showdown
Knowledge-focused CompletedThis trial is testing whether a new tablet form of the experimental drug PRAX-628 is absorbed by the body as well as the existing capsule form. Healthy volunteers will receive a single 40 mg dose of each version on separate occasions, and researchers will compare drug levels in t…
Phase 1 • Sponsor: Praxis Precision Medicines • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC